Opinion|Videos|January 10, 2025

Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

Name: Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
Uploaded: 2025-01-10T15:53:39.506Z
Duration: AJ4M22S
Description: Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

Author(s)Callie Coombs, MD , Matthew Davids, MD, MMSc , Seema Bhat, MD

Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.

Video content above is prompted by the following:

With the recent NCCN update recommending pirtobrutinib as a second line or later option, and in light of the BRUIN CLL-321 data presented at the 2024 American Society of Hematology annual meeting, what factors should oncologists consider when incorporating newer agents like pirtobrutinib into the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)?
What is the significance of novel Bruton tyrosine kinase (BTK) degraders such as NX-5948, and how might they fill therapeutic gaps in BTK-resistant or intolerant relapsed/refractory CLL populations?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape

Newsletter

Related Content

Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals

Understanding Gaps and Limitations in Current ITP Therapies

Emerging Agents Reshaping the ITP Landscape

AI, Genomic Testing Key to Advancing Precision Oncology: Vivek Subbiah, MD

Reshaping Myeloma Treatment: The Promise of Early ImmunotherapyWith Linvoseltamab

Latest CME

From Strict Avoidance to Tailored Therapies: Transforming Food Allergy Care

The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

Managing Schizophrenia: Evidence-Based Care and Optimizing Value of New and Emerging Therapies

Closing Gaps in CLL Care: Managed Care Insights and Strategies

Revolutionizing Acute Pain Relief: Emerging Non-Opioid Therapies and the Essential Role of Pharmacists

Overview and Burden of Migraine

The Role of the Pharmacist Migraine Management

The Evolving Treatment Landscape of Migraine

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care

New and Approved: FDA’s 2024 Drug Lineup

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Revolutionizing Acute Pain Relief: Emerging Nonopioid Therapies and the Essential Role of Managed Care

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

Overcoming Operational and Clinical Barriers in Multiple Myeloma: Managed Care Strategies for Antibody-Based Regimens

Exploring Therapeutic Advances in Myelofibrosis and Key Considerations for Effective Management

Driving Better Outcomes in Hypertrophic Cardiomyopathy: A Managed Care Imperative

Optimizing the Uptake of Long-Acting Injectables in HIV Treatment and Prevention: Considerations for Managed Care

Harnessing Data-Driven Insights and Innovations to Enhance AMD and DME Management: Strategic Approaches for Managed Care

Navigating the Advancements in Oral Therapy Options in HR+ Metastatic Breast Cancer

Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists

Managed Care Approaches and Models for Equitable Access to Innovations in Major Depressive Disorder Treatment

Evaluating the Effectiveness and Value of Novel Nonhormonal Treatments in the Management of Menopause-Related Vasomotor Symptoms

Updated Guidance and Managed Care Strategies to Optimize Respiratory Syncytial Virus Vaccination Coverage

Leveraging Biologics and Immunotherapies in the Management of Food Allergies

Advancing Care in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Optimizing Outcomes With Emerging Therapies

The Evolving Landscape of Transthyretin Amyloidosis Cardiomyopathy: New Therapies and Treatment Strategies

Reflecting on the Real-World Use of Biologic Therapy in Asthma Management

Advancing Cystic Fibrosis Management: The Evolving Role of Specialty and Managed Care Pharmacists

Pulmonary Arterial Hypertension: Real-World Applications of New Therapies and Management Strategies

Targeting Chronic Rhinosinusitis With Nasal Polyps With Biologics: Optimizing Outcomes and Reducing Health Care Burden

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

The Expanding Therapeutic Landscape in IgA Nephropathy: Applying Evidence-Based Strategies and Guideline Updates for Managed Care

Leveraging Novel Therapies to Transform Demodex Blepharitis Care (Pharmacy Technician Credit)

Leveraging Novel Therapies to Transform Demodex Blepharitis Care

The Changing Paradigm in Pain Management and Supporting Access to Novel Therapies

The Expanding Therapeutic Landscape in IgA Nephropathy: A Case-Based Exploration of Optimized Patient Outcomes

Opioids, Pain Management, and Substance Use Disorder: A Practical Overview

Trending on AJMC

Government Shutdown Could Disrupt Health Care Access

Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries

Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds

Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer

Colon Cancer Recurrence Risk Nearly Gone After 6 Years, Study Reveals